EE516 Cost-Effectiveness Analysis of Adjuvant Pembrolizumab Versus Standard-of-Care (SOC) Immunotherapies (High-Dose interferon Alfa 2-b or Ipilimumab) in High-Risk Resected Melanoma in United States (US)
Abstract
Authors
Syeda Hina Zaidi Roselyn Salomey Amamoo Ivo Abraham